WANG, RAYMOND Y.

Raymond Wang, M.D., is a board-certified clinical geneticist and biochemical genetics specialist, director of the Campbell Foundation Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s, Orange, CA, USA, the CHOC California Institute of Regenerative Medicine Alpha Stem Cell Program, and Associate Clinical Professor of Pediatrics at the University of California-Irvine School of Medicine. Dr Wang earned his medical degree from the University of California, Los Angeles (UCLA), where he was a member of the Alpha Omega Alpha honours society. He completed his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center, a fellowship in biochemical genetics at the UCLA Intercampus Training Program in 2007, and the UCLA K30 Graduate Program in Translational Investigation in 2008. Dr Wang’s National Institutes of Health-funded and Campbell Foundation Endowed Clinical / Translational Research Program has one main vision: to provide hope to patients and families with lysosomal diseases. To do so, its first mission is to provide access to investigational treatments for lysosomal storage disorder patients who currently have no approved / effective therapy. Its second mission is to conduct translational research and develop “next-generation” treatments for lysosomal metabolic patients. Dr Wang has been Principal Investigator for clinical trials of enzyme replacement therapies for mucopolysaccharidosis (MPS) types I, II, and VII, neuronal ceroid lipofuscinosis type 2, gene replacement therapy for GM1 gangliosidosis, MPS types I and IIIa, and various therapies for Niemann Pick type C. His translational research aims to study gene replacement / genomic editing to address skeletal myopathy in Pompe disease and refractory symptoms of MPS type I.